Kirsten Raun
Biography & Research Background
Kirsten Raun is a researcher at Novo Nordisk (Health Care Discovery, Department of GH Biology). Raun was the lead researcher in the original characterization of Ipamorelin, identifying it as the first growth hormone secretagogue with high selectivity for GH release without significantly stimulating ACTH or cortisol — distinguishing it from all earlier GHS compounds including GHRP-6 and GHRP-2. Her foundational 1998 paper 'Ipamorelin, the first selective growth hormone secretagogue' in the European Journal of Endocrinology established the compound's pharmacological uniqueness. She also co-authored 'Highly Potent Growth Hormone Secretagogues: Hybrids of NN703 and Ipamorelin' (2001). Kirsten Raun is referenced as a leading scientist in Ipamorelin research. In no way is this scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between Pure US Peptide and this scientist.
External Profiles
Authored Research Profiles (1)
Kirsten Raun is referenced as a leading researcher in the following peptide research profiles on Pure U.S. Peptides:
Kirsten Raun is being referenced as one of the leading scientists involved in the research and development of the peptides listed above. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of any product for any reason. There is no affiliation or relationship, implied or otherwise, between Pure U.S. Peptides and this researcher. The purpose of citing the researcher is to acknowledge, recognize, and credit the exhaustive research and development efforts conducted by the scientists studying these peptides.